Skip to main content

Table 4 Mean annual indirect costs

From: Clinical, humanistic, and economic burden of severe haemophilia B in adults receiving factor IX prophylaxis: findings from the CHESS II real-world burden of illness study in Europe

  SHL patients
(n = 25)
EHL patients
(n = 15)
All patients
(n = 40)
Total indirect costs €11,907 €4083 €8973
 Germany €2447
 Spain €16,001
 France €36,809
 Italy €4340
 UK €3552
Early retirement/work stoppage €7515 €1846 €5389
 Germany €2447
 Spain €16,001
 France €36,809
 Italy €4340
 UK €3552
Patient lost productivity €1619 €1158 €1446
 Germany €2447
 Spain €426
 France €0
 Italy €654
 UK €3552
Caregiver lost productivity €2773 €1079 €2138
 Germany €0
 Spain €6345
 France €0
 Italy €851
 UK €0
  1. EHL, extended half-life; SHL, short half-life
  2. Note: Sample sizes for country-level costs for each outcome were too small to be meaningful, and not included here